Consistent clinical outcomes have been achieved using both the originator infliximab (IFX) and a biosimilar infliximab in patients with inflammatory bowel disease (IBD), an international expert has told Australian clinicians. Furthermore, immune responses to the biosimilar infliximab ‘Inflectra’ very closely resemble those to the originator product ‘Remicade®’, Dr Milan Lukáš, from the IBD Clinical Research ...
International expert shares clinical experience of using biosimilar infliximab in IBD
7 Dec 2016
Sponsored by Pfizer Australia